Edition:
India

Jounce Therapeutics Inc (JNCE.OQ)

JNCE.OQ on NASDAQ Stock Exchange Global Select Market

12.52USD
15 Dec 2017
Change (% chg)

$-0.29 (-2.26%)
Prev Close
$12.81
Open
$12.81
Day's High
$13.05
Day's Low
$12.51
Volume
645,227
Avg. Vol
68,002
52-wk High
$29.29
52-wk Low
$11.05

Latest Key Developments (Source: Significant Developments)

Jounce Therapeutics reports Q3 loss $0.13/shr
Monday, 13 Nov 2017 

Nov 13 (Reuters) - Jounce Therapeutics Inc :Jounce Therapeutics reports third quarter 2017 financial results.Q3 loss per share $0.13.Q3 earnings per share view $-0.25 -- Thomson Reuters I/B/E/S.Jounce Therapeutics Inc- ‍remain on track to announce preliminary efficacy data for phase 1/2 iconic study in 1H 2018​.Jounce Therapeutics Inc - ‍jounce has narrowed its financial guidance previously provided for full year 2017​.Jounce Therapeutics Inc- ‍now expects to use approximately $100.0 million to $110.0 million in cash for full year 2017​.Jounce Therapeutics Inc- ‍collaboration revenue was $18.1 million for Q3 of 2017, compared to $16.9 million for same period in 2016​.Jounce Therapeutics Inc- ‍as of Sept 30, 2017, cash, cash equivalents and investments were $283.4 million, compared to $257.4 million as of Dec 31, 2016​.Jounce Therapeutics - now expects collaboration revenue from non-cash amortization of Celgene upfront payment​ for FY 2017 to be $70 million to $75 million.  Full Article

Partner Fund Management L.P reports 5.4 pct passive stake in Jounce Therapeutics
Saturday, 30 Sep 2017 

Sept 29 (Reuters) - Jounce Therapeutics Inc :Partner Fund Management L.P reports 5.4 percent passive stake in Jounce Therapeutics Inc as of Sept 19, 2017 - SEC Filing.  Full Article

Jounce Therapeutics reports Q2 loss of $0.11/shr
Wednesday, 9 Aug 2017 

Aug 9 (Reuters) - Jounce Therapeutics Inc :Jounce Therapeutics reports second quarter 2017 financial results.Q2 loss per share $0.11.Q2 earnings per share view $-0.15 -- Thomson Reuters I/B/E/S.Jounce Therapeutics Inc - ‍ reiterates financial guidance previously provided for full year 2017​.Jounce Therapeutics Inc - ‍ expects to use approximately $100.0 to $120.0 million in cash for full year 2017​.Jounce Therapeutics Inc qtrly ‍collaboration revenue-related party $20.3 million.  Full Article

BRIEF-Jounce Therapeutics reports Q3 loss $0.13/shr

* Jounce Therapeutics reports third quarter 2017 financial results